BioSpace News Archive

3DCERAM Sinto, Inc. (3DCERAM Sinto Inc; https://sintoamerica.com/3dceram-sinto-usa/), a turnkey provider for additive manufacturing of advanced ceramics, and SINTX Technologies, Inc. (www.sintx.com) (NASDAQ: SINT; “SINTX” or the “Company”), a manufacturer of advanced ceramics for biomedical and technical markets, announced today a collaboration to develop multiple novel resins and processes for the additive manufacturing of ceramic products.

On August 9, Agile Therapeutics released its second-quarter financial results, showing significant growth in revenue from its innovative weekly birth control patch, Twirla®, and a widening gross margin thanks to net revenue growth and decreasing operating expenses.

Response Pharmaceuticals, Inc. today announced the successful completion of its Phase 1B clinical trial for the company’s lead drug candidate, RDX-002, a first-in-class inhibitor of intestinal microsomal triglyceride transfer protein (iMTP).

Annual Awards Program Recognizes Innovation in Agricultural and Food Technologies Around the Globe

A Leap Forward for Patients, A Promising Opportunity for Investors, and a Revolutionary Tool for Physicians

Ultrasensitive immunoassays developer Spear Bio has announced that it has received ISO certification for operating a “Quality Management System which complies with the requirements of ISO 13485: 2016.”

Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced plans to release its financial results for the second quarter ended June 30, 2023 by Friday, August 25, 2023 prior to the open of the financial markets.

Geron Corporation reported that it has granted non-statutory stock options to purchase an aggregate of 189,850 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company.

RoslinCT, a leading contract development and manufacturing organization (CDMO) for Advanced Cell and Gene therapies, announced the appointment of Derek Hei, Ph.D., to its Scientific Advisory Board (SAB).

TheracosBio and SmithRx, a next-generation pharmacy benefits management (PBM) company, today announced that SmithRx will offer access to BRENZAVVY™ (bexagliflozin), TheracosBio’s FDA-approved oral medication for adults with type 2 diabetes, through its partnership with Mark Cuban Cost Plus Drug Company (Cost Plus Drugs).